# Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients

> **NCT02847455** · PHASE2,PHASE3 · COMPLETED · sponsor: **Livzon Pharmaceutical Group Inc.** · enrollment: 408 (actual)

## Conditions studied

- Duodenal Ulcer

## Interventions

- **DRUG:** 5 mg ilaprazole
- **DRUG:** 10 mg ilaprazole
- **DRUG:** 10 mg Rabeprazole

## Key facts

- **NCT ID:** NCT02847455
- **Lead sponsor:** Livzon Pharmaceutical Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-10
- **Final completion:** —
- **Target enrollment:** 408 (ACTUAL)
- **Last updated:** 2016-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02847455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02847455, "Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02847455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*